Theravance, Inc.

Theravance Biopharma R&d Ip, LLC

Theravance Biopharma Antibiotics Ip, LLC

Weijiang Zhang

Adam D Hughes

Mathai Mammen

Yu-Hua Ji

Li Li

Robert S Chao

Junning Lee

Pierre-Jean Colson

Xiaojun Huang

Daniel D Long

Robert Murray McKinnell

Lan Jiang

Eric L Stangeland

Sheila M Zipfel

Venkat R Thalladi

Daisuke Roland Saito

David A Oare

Lori Jean Van Orden

Ioanna Stergiades

Jerry Nzerem

Mandy Loo

Gene Timothy Fass

Gavin Ogawa

Michael Robert Tracey

Kassandra Lepack

Dimitar Filipov

Timothy Fass

Edward Yost

Jack Green

Ronnie Cheung

Cristin Hubbard

Matthew J Peterson

Richard J Lee

Davar Khossravi

The present invention relates to a compound of formula I: 

Hydrochloride salts of a glycopeptide-cephalosporin antbiotic compond

The invention relates to a crystalline form of a triethylamine salt of (2Z)-2-(2 -amino-5-chlorothiazol-4-yl)-2-(3-N-tert-butoxycarbonylaminopropoxyimino)acetic acid. The invention also relates to processes and intermediates for preparing the crystalline form. The crystalline form is useful as an intermediate for preparing cross-linked glycopeptide-cephalosporin antibiotics.

Crystalline form of a substituted thiazolylacetic acid triethylamine salt

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

Inhibitors of hepatitis C virus

The invention provides processes for preparing intermediates useful for preparing compounds of the formula: or a salt thereof, where Rare as defined in the specification.

Process for preparing biphenyl imidazole compounds

The invention provides crystalline solid forms of (((S)-1-{(S)-2-[4-(4'-{[6-((2R,5S)-2,5-dimethyl-4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2&#x2032;-trifluoromethoxy-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat hepatitis C virus infection, and processes useful for preparing such crystalline solid forms.

Crystalline form of a pyridyl-piperazinyl hepatitis C virus inhibitor

The invention provides a crystalline freebase form of 4'-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3&#x2032;-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.

Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

The invention provides a crystalline freebase form of 4'-{2-ethoxy-4-ethyl-5-[((S) -2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3&#x2032;-fluorobiphenyl-2 -carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases such as hypertension.

This invention provides 4-amino-1-(pyridylmethyl)piperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome and chronic obstructive pulmonary disease, using such compounds.

Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds

The invention provides a novel &#x3b2;adrenergic receptor agonist in crystalline salt form. The invention also provides pharmaceutical compositions comprising the novel &#x3b2;adrenergic receptor agonist in crystalline salt form, formulations containing the pharmaceutical compositions, methods of using the crystalline salt to treat diseases associated with &#x3b2;adrenergic receptor activity, and processes useful for preparing such crystalline compounds.

[object Object]

This invention is directed to compounds of formula I: 

Substituted pyrrolidine and related compounds

This invention is directed to compounds of formula I:  wherein R-Rand a-e are as defined in the specification; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. The invention also directed to pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors using such compounds.

Processes and intermediates for preparing substituted 4-amino-1-(pyridylmethyl)-piperidine and related compounds in high yield and high purity are described. The substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds prepared by the described processes are useful as muscarinic receptor antagonists.

Growing community of inventors

Concord, CA, United States of America

Weijiang Zhang